Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Epizyme Inc (NQ: EPZM )

8.095 USD -0.135 (-1.64%)
Official Closing Price Updated: 6:18 PM EDT, Apr 16, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Epizyme Inc

< Previous 1 2 3 4 5 6 7 8 9 Next >
Epizyme Outlines Clinical Progress, TAZVERIK Development Strategy and Pipeline Priorities During Company’s Strategic Vision Call
Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, hosted a call today outlining the Company’s strategic... 
From Business Wire News Releases
Epizyme to Host Strategic Vision Call on March 2, 2021
Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that it will host a call to discuss the... 
From Business Wire News Releases
CORRECTING and REPLACING Epizyme Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results
Third subhead of release should read: Safety Run-In Portion of Confirmatory Trials of TAZVERIK® in ES and FL and Phase 1b Portion of Phase 1b/2 Castration-Resistant Prostate Cancer Fully Enrolled;... 
From Business Wire News Releases
Epizyme Announces Date of Fourth Quarter and Full Year 2020 Financial Results and Participation in Upcoming Investor Conferences
Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that management will host a conference call... 
From Business Wire News Releases
Enthera Pharmaceuticals Appoints Kazumi Shiosaki to Its Board of Directors and Lisa Olson to Its Scientific Advisory Board to Push Forward Company Growth and Development
Enthera Pharmaceuticals appoints Kazumi Shiosaki to its Board of Directors and Lisa Olson to its Scientific Advisory Board 
From Business Wire News Releases
Epizyme to Participate in Jefferies Virtual London Healthcare Conference
Epizyme to Participate in Jefferies Virtual London Healthcare Conference 
From Business Wire News Releases
Epizyme Reports Business Progress and Third Quarter 2020 Financial Results
Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today provided business and portfolio updates and reported... 
From Business Wire News Releases
Epizyme Announces Expanded Loan Facility with Pharmakon Advisors for Additional $150 Million to Fund its Growth Initiatives
Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that the company has entered into an... 
From Business Wire News Releases
Epizyme Announces Date of Third Quarter 2020 Financial Results
Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that management will host a conference call... 
From Business Wire News Releases
Epizyme Announces Two Lancet Oncology Publications on TAZVERIK® (tazemetostat) Phase 2 Data in Epithelioid Sarcoma and Follicular Lymphoma
Epizyme Announces Two Lancet Oncology Publications on TAZVERIK® (tazemetostat) Phase 2 Data in Epithelioid Sarcoma and Follicular Lymphoma 
From Business Wire News Releases
Epizyme to Participate in Morgan Stanley 18th Annual Global Healthcare Conference
Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that Robert Bazemore, president and... 
From Business Wire News Releases
Epizyme Reports Business Progress and Second Quarter 2020 Financial Results
Epizyme Reports Business Progress and Second Quarter 2020 Financial Results 
From Business Wire News Releases
Epizyme Announces Date of Second Quarter 2020 Financial Results and Participation at 2020 Wedbush PacGrow Healthcare Virtual Conference
Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that management will host a conference... 
From Business Wire News Releases
Epizyme Announces U.S. FDA Accelerated Approval of TAZVERIK™ (tazemetostat) for Relapsed/Refractory Follicular Lymphoma
Epizyme Announces U.S. FDA Accelerated Approval of TAZVERIK™ (tazemetostat) for Relapsed/Refractory Follicular Lymphoma 
From Business Wire News Releases
Epizyme to Present Data from Tazemetostat Clinical Program during the 2020 ASCO Virtual Scientific Program
Epizyme to Present Data from Tazemetostat Clinical Program during the 2020 ASCO Virtual Scientific Program 
From Business Wire News Releases
Epizyme Reports Business Progress and First Quarter 2020 Financial Results
Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing novel epigenetic therapies, today provided business and pipeline updates and reported first quarter... 
From Business Wire News Releases
Epizyme Announces Date of First Quarter 2020 Financial Results
Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing novel epigenetic therapies, today announced that management will host a conference call and... 
From Business Wire News Releases
Epizyme Appoints Jeffery Kutok, M.D., Ph.D., as Chief Scientific Officer
Epizyme Appoints Jeffery Kutok, M.D., Ph.D., as Chief Scientific Officer 
From Business Wire News Releases
Epizyme Provides Business Update and Reports Fourth Quarter and Full Year 2019 Financial Results
Epizyme Provides Business Update and Reports Fourth Quarter and Full Year 2019 Financial Results 
From Business Wire News Releases
Epizyme Announces Date of Fourth Quarter and Full Year 2019 Results and Presentations at Upcoming Investor Conferences
Epizyme, Inc. (Nasdaq: EPZM), a biopharmaceutical company developing novel epigenetic therapies, today announced that management will host a conference call and webcast to discuss its fourth quarter... 
From Business Wire News Releases
Epizyme Announces FDA Acceptance of New Drug Application for Filing with Priority Review for TAZVERIK™ (tazemetostat) for the Treatment of Follicular Lymphoma
Epizyme Announces FDA Acceptance of New Drug Application for Filing with Priority Review for TAZVERIK™ (tazemetostat) for the Treatment of FL 
From Business Wire News Releases
Epizyme Announces U.S. FDA Accelerated Approval of TAZVERIK™ (tazemetostat) for the Treatment of Patients with Epithelioid Sarcoma
Epizyme Announces U.S. FDA Accelerated Approval of TAZVERIK™ (tazemetostat) for the Treatment of Patients with Epithelioid Sarcoma 
From Business Wire News Releases
Epizyme Announces Exercise of $50 Million Option with Royalty Pharma and Highlights Key 2020 Initiatives to Build Long-Term Value
Epizyme Announces Exercise of $50 Million Option with Royalty Pharma and Highlights Key 2020 Initiatives to Build Long-Term Value 
From Business Wire News Releases
Epizyme Submits New Drug Application to the U.S. FDA for Tazemetostat for the Treatment of Patients with Follicular Lymphoma
Epizyme Submits New Drug Application to the U.S. FDA for Tazemetostat for the Treatment of Patients with Follicular Lymphoma 
From Business Wire News Releases
Epizyme Announces FDA Advisory Committee Votes Unanimously in Favor of Tazemetostat for the Treatment of Patients with Epithelioid Sarcoma
Epizyme Announces FDA Advisory Committee Votes Unanimously in Favor of Tazemetostat for the Treatment of Patients with Epithelioid Sarcoma 
From Business Wire News Releases
Epizyme (EPZM) Trading of Stock Halted; Oncology Drug Advisory Committee to Review Tazemetostat at 8:00 a.m. ET Today
Epizyme (EPZM) Trading of Stock Halted as Oncology Drug Advisory Committee Reviews Tazemetostat 
From Business Wire News Releases
Cancer Drug Revenues Expected to be Largest Share in Pharma Market
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Cancer Drug Revenues Expected to be Largest Share in Pharma Market
Financialnewsmedia.com News Commentary 
From PR Newswire
Epizyme Presents Updated Phase 2 Data at the 2019 ASH Annual Meeting Supporting Planned Tazemetostat NDA Submission for Follicular Lymphoma
Epizyme Presents Updated Phase 2 Data at the 2019 ASH Annual Meeting Supporting Planned Tazemetostat NDA Submission for Follicular Lymphoma 
From Business Wire News Releases
Epizyme Announces FDA Advisory Committee Meeting to Review Tazemetostat for the Treatment of Patients with Epithelioid Sarcoma
Epizyme Announces FDA Advisory Committee Meeting to Review Tazemetostat for the Treatment of Patients with Epithelioid Sarcoma 
From Business Wire News Releases
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.